These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3243734)

  • 1. In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria.
    Collins CH; Uttley AH
    J Antimicrob Chemother; 1988 Dec; 22(6):857-61. PubMed ID: 3243734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro susceptibility of mycobacteria to ciprofloxacin.
    Collins CH; Uttley AH
    J Antimicrob Chemother; 1985 Nov; 16(5):575-80. PubMed ID: 2934361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of mycobacteria species other than Mycobacterium tuberculosis to amikacin, cephalosporins and cefoxitin.
    Haas H; Michel J; Sacks TG
    Chemotherapy; 1982; 28(1):1-5. PubMed ID: 7056128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.
    Young LS; Berlin OG; Inderlied CB
    Am J Med; 1987 Apr; 82(4A):23-6. PubMed ID: 3107379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sensitivity of 7 mycobacterial species to new quinolones].
    Gevaudan MJ; Mallet MN; Gulian C; Terriou P; Lagier P; de Micco P
    Pathol Biol (Paris); 1988 May; 36(5):477-81. PubMed ID: 3136429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibiogram of mycobacteria for erythromycin, tetracycline and cotrimoxazole].
    Demoulin L; Médard M; Kellens J
    Pathol Biol (Paris); 1983 Mar; 31(3):195-7. PubMed ID: 6343976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenoxazine compounds produced by the reactions with bovine hemoglobin show antimicrobial activity against non-tuberculosis mycobacteria.
    Shimizu S; Suzuki M; Tomoda A; Arai S; Taguchi H; Hanawa T; Kamiya S
    Tohoku J Exp Med; 2004 May; 203(1):47-52. PubMed ID: 15185971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
    Yates MD; Collins CH
    Tubercle; 1981 Jun; 62(2):117-21. PubMed ID: 7303160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].
    Dailloux M; Petitpain N; Henry C; Weber M
    Pathol Biol (Paris); 1989 May; 37(5):346-9. PubMed ID: 2780092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
    Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
    PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sensitivity to levofloxacin of various types of non-tuberculosis Mycobacterium].
    Otten TF; Solov'eva NS; Vishnevskiĭ BI
    Antibiot Khimioter; 2002; 47(6):34-7. PubMed ID: 12422647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulfadimethoxine as a promising drug in the treatment of infections caused by Mycobacterium kansasii and Mycobacterium xenopi--differentiation between M. kansasii and M. marinum and between M. gordonae and M. scrofulaceum by the susceptibility testing to sulfadimethoxine].
    Tsukamura M
    Kekkaku; 1989 Apr; 64(4):313-7. PubMed ID: 2747117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
    Wang HX; Yue J; Han M; Yang JH; Gao RL; Jing LJ; Yang SS; Zhao YL
    Chin Med J (Engl); 2010 Jan; 123(2):184-7. PubMed ID: 20137367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.
    Gay JD; DeYoung DR; Roberts GD
    Antimicrob Agents Chemother; 1984 Jul; 26(1):94-6. PubMed ID: 6236748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
    Texier-Maugein J; Mormède M; Fourche J; Bébéar C
    Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.
    Wallace RJ; Dalovisio JR; Pankey GA
    Antimicrob Agents Chemother; 1979 Nov; 16(5):611-4. PubMed ID: 526002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of trimethoprim and sulfamethoxazole against the nontuberculous mycobacteria.
    Wallace RJ; Wiss K; Bushby MB; Hollowell DC
    Rev Infect Dis; 1982; 4(2):326-31. PubMed ID: 7111959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.